NKGen Biotech Expands Alzheimer’s Trial Network to Boost Enrollment
Event summary
- NKGen Biotech activated three new clinical trial sites in New Jersey, New York, and Florida for its Phase 2 Alzheimer’s trial.
- The expansion aims to improve patient access and enrollment in the Northeast and Southeast regions.
- Troculeucel, the investigational therapy, is an autologous NK cell-based treatment for moderate Alzheimer’s disease.
- The trial is registered on ClinicalTrials.gov under identifier NCT06189963.
The big picture
NKGen Biotech’s expansion of its Alzheimer’s trial network reflects a strategic push to overcome enrollment challenges in neurodegenerative disease studies. The move aligns with broader industry efforts to decentralize clinical trials and improve access for underserved patient populations. Success in this phase could position troculeucel as a competitive NK cell therapy in a market with limited approved treatments for moderate Alzheimer’s.
What we're watching
- Enrollment Momentum
- Whether the expanded site network will accelerate patient recruitment and meet enrollment targets.
- Geographic Reach
- How the addition of Northeast sites impacts regional participation and referral patterns.
- Therapeutic Validation
- The pace at which troculeucel demonstrates efficacy in a broader patient population.
Related topics